Latest news with #MedicalEquipment
Associated Press
2 hours ago
- Business
- Associated Press
GenHealth.ai Launches AI-Powered Order Automation Solution for Home and Durable Medical Equipment (HME / DME) Providers
Revolutionizing DME Operations: Seamless Automation from Intake to Billing BOSTON, MASSACHUSETTS / ACCESS Newswire / June 4, 2025 / today announced the launch of its AI-powered automation solution specially designed for Durable Medical Equipment (DME) and Home Medical Equipment (HME) providers, helping relieve the burden of complex workflows such as medical order intake, eligibility verification, and prior authorizations. This launch marks a major expansion of 's mission to bring intelligent, scalable automation to healthcare operations-boosting accuracy, reducing delays, and accelerating access to care. Developed in close partnership with early DME customers, 's platform streamlines the medical order lifecycle using new advancements in AI and Large Language Models (LMMs)-combined with deep integrations into existing EMR and billing systems-specifically for DME and HME providers. Key capabilities include: Early Results: Less Manual Work. Higher Accuracy Across early implementations, has delivered: 'With AI, customers are able to bring on our AI agent to help their existing teams process more cases and increase revenue while reducing administrative costs.' said Ethan Siegel, CPO. Ricky Sahu, CEO, added 'DME providers deserve tools that reduce friction across every step of the order process-and they shouldn't have to rip out their systems to make it work. Our AI integrates into existing customer apps without disrupting how their teams work today.' Expanding the Vision for Smarter Healthcare Operations In addition to the DME solution, has developed a prior authorization automation solution for providers, designed to accelerate access to high-cost therapies such as GLP-1s and chemotherapies. By combining AI, patient charts, and payer-specific coverage logic, the platform helps providers achieve faster patient-centered approvals-resulting in higher approval rates. will be showcasing these capabilities live at the VGM Heartland Conference in Waterloo, IA, on June 10-11, 2025 and at ENDO 2025 in San Francisco, CA, on July 12-14, 2025. About is a healthcare automation company building AI-powered infrastructure for modern care delivery. The company's platform uses a proprietary Large Medical Model (LMM) to understand real-world clinical data, payer requirements, and operational workflows. helps providers, DME suppliers, and care teams reduce administrative burden, improve accuracy, and accelerate patient access to care-all through intelligent, end-to-end automation. To learn more, contact [email protected] or visit Contact Information Mike Maseda Head of Operations [email protected] SOURCE: Genhealth AI press release
Yahoo
3 days ago
- Business
- Yahoo
There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on Abbott Laboratories is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.11 = US$7.9b ÷ (US$81b - US$13b) (Based on the trailing twelve months to March 2025). Therefore, Abbott Laboratories has an ROCE of 11%. In absolute terms, that's a pretty normal return, and it's somewhat close to the Medical Equipment industry average of 10%. See our latest analysis for Abbott Laboratories In the above chart we have measured Abbott Laboratories' prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Abbott Laboratories . Investors would be pleased with what's happening at Abbott Laboratories. The data shows that returns on capital have increased substantially over the last five years to 11%. Basically the business is earning more per dollar of capital invested and in addition to that, 22% more capital is being employed now too. So we're very much inspired by what we're seeing at Abbott Laboratories thanks to its ability to profitably reinvest capital. In summary, it's great to see that Abbott Laboratories can compound returns by consistently reinvesting capital at increasing rates of return, because these are some of the key ingredients of those highly sought after multi-baggers. And investors seem to expect more of this going forward, since the stock has rewarded shareholders with a 62% return over the last five years. In light of that, we think it's worth looking further into this stock because if Abbott Laboratories can keep these trends up, it could have a bright future ahead. Like most companies, Abbott Laboratories does come with some risks, and we've found 1 warning sign that you should be aware of. While Abbott Laboratories may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18-05-2025
- Business
- Yahoo
Why PULSION Medical Systems SE (MUN:PUS) Looks Like A Quality Company
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. We'll use ROE to examine PULSION Medical Systems SE (MUN:PUS), by way of a worked example. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for PULSION Medical Systems is: 24% = €5.0m ÷ €21m (Based on the trailing twelve months to December 2024). The 'return' is the profit over the last twelve months. Another way to think of that is that for every €1 worth of equity, the company was able to earn €0.24 in profit. Check out our latest analysis for PULSION Medical Systems One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. Pleasingly, PULSION Medical Systems has a superior ROE than the average (9.5%) in the Medical Equipment industry. That's clearly a positive. Bear in mind, a high ROE doesn't always mean superior financial performance. A higher proportion of debt in a company's capital structure may also result in a high ROE, where the high debt levels could be a huge risk . You can see the 3 risks we have identified for PULSION Medical Systems by visiting our risks dashboard for free on our platform here. Virtually all companies need money to invest in the business, to grow profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. That will make the ROE look better than if no debt was used. Shareholders will be pleased to learn that PULSION Medical Systems has not one iota of net debt! Its high ROE already points to a high quality business, but the lack of debt is a cherry on top. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities. Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. In our books, the highest quality companies have high return on equity, despite low debt. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE. Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. Check the past profit growth by PULSION Medical Systems by looking at this visualization of past earnings, revenue and cash flow. But note: PULSION Medical Systems may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
17-05-2025
- Business
- Yahoo
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learning-by-doing, we'll look at ROE to gain a better understanding of DexCom, Inc. (NASDAQ:DXCM). ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for DexCom is: 24% = US$535m ÷ US$2.3b (Based on the trailing twelve months to March 2025). The 'return' refers to a company's earnings over the last year. That means that for every $1 worth of shareholders' equity, the company generated $0.24 in profit. Check out our latest analysis for DexCom One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. Pleasingly, DexCom has a superior ROE than the average (12%) in the Medical Equipment industry. That is a good sign. However, bear in mind that a high ROE doesn't necessarily indicate efficient profit generation. Especially when a firm uses high levels of debt to finance its debt which may boost its ROE but the high leverage puts the company at risk. Virtually all companies need money to invest in the business, to grow profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. It's worth noting the high use of debt by DexCom, leading to its debt to equity ratio of 1.08. There's no doubt the ROE is impressive, but it's worth keeping in mind that the metric could have been lower if the company were to reduce its debt. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it. Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE. But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So you might want to check this FREE visualization of analyst forecasts for the company. But note: DexCom may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
Koninklijke Philips First Quarter 2025 Earnings: EPS Beats Expectations
Revenue: €4.10b (down 1.0% from 1Q 2024). Net income: €82.0m (up from €1.00b loss in 1Q 2024). Profit margin: 2.0% (up from net loss in 1Q 2024). EPS: €0.089 (up from €1.09 loss in 1Q 2024). We've discovered 3 warning signs about Koninklijke Philips. View them for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 130%. Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Performance of the market in the Netherlands. The company's shares are down 3.8% from a week ago. You should learn about the 3 warning signs we've spotted with Koninklijke Philips (including 2 which make us uncomfortable). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
